Weidong Yin, Getty Images (Peter Parks)

Sino­vac posts pos­i­tive PhI/II da­ta for their Covid-19 vac­cine as re­searchers rush in­to a piv­otal test

Bei­jing-based Sino­vac has post­ed a pos­i­tive pre­lim­i­nary snap­shot of hu­man da­ta from the Phase I/II study of their vac­cine for coro­n­avirus, show­ing that the jab was able to safe­ly spur pro­tec­tive an­ti­bod­ies in more than 90% of the vol­un­teers in­volved.

The biotech re­port­ed Sat­ur­day that they had re­cruit­ed 743 pa­tients for the two-step tri­al, with 143 in Phase I and the rest in Phase II.

“The neu­tral­iz­ing an­ti­body se­ro­con­ver­sion rate is above 90%,” the com­pa­ny states, “which con­cludes the vac­cine can­di­date can in­duce pos­i­tive im­mune re­sponse.” That’s about all you’re get­ting at this stage of the process, though, with lit­tle hard da­ta in their state­ment to de­ci­pher.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.